Table 1 Baseline participant characteristics
Placebo (N = 7) | CT1812 100 mg (N = 8) | CT1812 300 mg (N = 8) | Total (N = 23) | |
|---|---|---|---|---|
Age (years) | 72.6 ± 5.8 | 68.0 ± 9.3 | 69.6 ± 10.9 | 70.0 ± 8.8 |
Sex | 4 M, 3 F | 4 M, 4 F | 4 M, 4 F | 12 M, 11 F |
Race | ||||
Black or African American | 1 (14%) | - | - | 1 (4%) |
White | 6 (86%) | 8 (100%) | 8 (100%) | 22 (96%) |
Ethnicity | ||||
Hispanic or Latino | - | - | - | - |
Not Hispanic or Latino | 7 (100%) | 8 (100%) | 8 (100%) | 23 (100%) |
Weight (kg) | 74.8 ± 9.2 | 85.6 ± 5.0 | 76.2 ± 16.9 | 79.0 ± 12.1 |
Height (cm) | 172.1 ± 12.1 | 171.4 ± 12.5 | 170.3 ± 9.9 | 171.2 ± 11.0 |
BMI (kg/m2) | 25.2 ± 1.8 | 29.5 ± 4.1 | 26.3 ± 5.7 | 27.1 ± 4.5 |
Education level achieved | ||||
High school or GED | 2 (29%) | - | 1 (13%) | 3 (13%) |
College or some college | 2 (29%) | 5 (63%) | 7 (88%) | 14 (61%) |
Postgraduate | 3 (43%) | 3 (38%) | - | 6 (26%) |
ApoE status | ||||
APOE4 carrier | 6 (86%) | 7 (88%) | 5 (63%) | 18 (78%) |
APOE4 non-carrier | 1 (14%) | 1 (13%) | 3 (38%) | 5 (22%) |
MMSE (Total score) | 22.3 ± 1.98 | 22.6 ± 1.51 | 22.9 ± 2.42 | 22.6 ± 1.92 |
Use of AD drugs | ||||
ACHEI | 6 (86%) | 7 (88%) | 7 (88%) | 20 (87%) |
Memantine | 3 (43%) | 1 (13%) | 3 (38%) | 7 (30%) |